These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32923128)

  • 1. A liposomal RNA vaccine inducing neoantigen-specific CD4
    Salomon N; Vascotto F; Selmi A; Vormehr M; Quinkhardt J; Bukur T; Schrörs B; Löewer M; Diken M; Türeci Ö; Sahin U; Kreiter S
    Oncoimmunology; 2020 Jun; 9(1):1771925. PubMed ID: 32923128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
    Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.
    Kawahara M; Takaku H
    Cancer Biol Ther; 2015; 16(11):1616-25. PubMed ID: 26391871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbon Ion and Photon Radiation Therapy Show Enhanced Antitumoral Therapeutic Efficacy With Neoantigen RNA-LPX Vaccines in Preclinical Colon Carcinoma Models.
    Salomon N; Helm A; Selmi A; Fournier C; Diken M; Schrörs B; Scholz M; Kreiter S; Durante M; Vascotto F
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):936-945. PubMed ID: 38163521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy.
    Huff AL; Longway G; Mitchell JT; Andaloori L; Davis-Marcisak E; Chen F; Lyman MR; Wang R; Mathew J; Barrett B; Rahman S; Leatherman J; Yarchoan M; Azad NS; Yegnasubramanian S; Kagohara LT; Fertig EJ; Jaffee EM; Armstrong TD; Zaidi N
    JCI Insight; 2023 Dec; 8(23):. PubMed ID: 38063199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immunogenic personal neoantigen vaccine for patients with melanoma.
    Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
    Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH
    PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
    Costa-Nunes C; Cachot A; Bobisse S; Arnaud M; Genolet R; Baumgaertner P; Speiser DE; Sousa Alves PM; Sandoval F; Adotévi O; Reith W; Protti MP; Coukos G; Harari A; Romero P; Jandus C
    Clin Cancer Res; 2019 Jul; 25(14):4320-4331. PubMed ID: 31015344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral-based vaccine promotes neoantigen-specific CD8
    D'Alise AM; Brasu N; De Intinis C; Leoni G; Russo V; Langone F; Baev D; Micarelli E; Petiti L; Picelli S; Fakih M; Le DT; Overman MJ; Shields AF; Pedersen KS; Shah MA; Mukherjee S; Faivre T; Delaite P; Scarselli E; Pace L
    Sci Transl Med; 2022 Aug; 14(657):eabo7604. PubMed ID: 35947675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
    Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
    Front Immunol; 2019; 10():2472. PubMed ID: 31749795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1
    Yamauchi T; Hoki T; Oba T; Kajihara R; Attwood K; Cao X; Ito F
    Cancer Immunol Immunother; 2022 Jan; 71(1):137-151. PubMed ID: 34037810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.